Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06220864 · ClinicalTrials.gov registry record · Phase 1

SNV1521 in Participants with Advanced Solid Tumors

A Phase 1 study of Advanced Solid Tumor, sponsored by Synnovation Therapeutics.

Recruiting
Registry status
Phase 1
Development phase
200
Enrollment target
9
Study locations

NCT06220864 is a Phase 1 study of Advanced Solid Tumor that is actively recruiting participants, run by Synnovation Therapeutics. The registered enrollment target is 200 participants, roughly in line with the 192-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target. The trial reports 9 study locations across 9 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06220864, a Phase 1 study of Advanced Solid Tumor, is actively recruiting participants, sponsored by Synnovation Therapeutics.

RECRUITING
Registry status
Phase 1
Development phase
200 participants
Enrollment target
9
Study locations

Study Summary

This study is testing a new medicine, SNV1521, for people with advanced cancers. The researchers want to find out if SNV1521 is safe, well-tolerated, and effective in treating solid tumors. They are investigating different doses in order to find the most effective and safe one. They are also investigating whether it can be combined with other cancer therapies.

Conditions Studied

Advanced Solid Tumor

Interventions

  • DRUG Trastuzumab Deruxtecan
  • DRUG SNV1521

Study Locations (9)

Connecticut

  • Yale University - New Haven

Pennsylvania

  • Thomas Jefferson University - Philadelphia

Tennessee

  • Sarah Cannon Research Institute - Nashville

Texas

  • The University of Texas M.D. Anderson Cancer Center - Houston

Utah

  • START Center for Cancer Care - West Valley City

New South Wales

  • Scientia Clinical Research - Randwick

Queensland

  • Princess Alexandra Hospital - Woolloongabba

Victoria

  • The Alfred Hospital - Melbourne

Trial Details

FieldValue
Enrollment Target 200 participants
Start Date 2024-02-23
Est. Completion 2026-12
Phase Phase 1

Sponsor

Synnovation Therapeutics

1 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06220864

The ClinicalTrials.gov registry entry for NCT06220864 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 192-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target. The listed sponsor is Synnovation Therapeutics, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Advanced Solid Tumor appearing as the primary indexed condition, and to 2 interventions - of which Trastuzumab Deruxtecan is the first listed.

NCT06220864 reports 9 study locations spanning 9 distinct geographic areas - top geographies include Connecticut, Pennsylvania, Tennessee.

Frequently Asked Questions

What is clinical trial NCT06220864 about?

NCT06220864 is a clinical study titled "SNV1521 in Participants with Advanced Solid Tumors". This study is testing a new medicine, SNV1521, for people with advanced cancers. The researchers want to find out if SNV1521 is safe, well-tolerated, and effective in treating solid tumors. They are investigating different doses in order to find the most effective and safe one. They are also investi...

What is the current status of trial NCT06220864?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 200 participants. The study started on 2024-02-23. Estimated completion is 2026-12.

What conditions does trial NCT06220864 study?

This clinical trial studies the following conditions: Advanced Solid Tumor.

What interventions are being tested in trial NCT06220864?

The interventions under investigation include: Trastuzumab Deruxtecan (DRUG), SNV1521 (DRUG).

Who is sponsoring clinical trial NCT06220864?

This trial is sponsored by Synnovation Therapeutics, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06220864 being conducted?

This trial has 9 study locations across Connecticut, Pennsylvania, Tennessee, Texas, Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Advanced Solid Tumor

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Advanced Solid Tumor

All registered trials for this condition

Connecticut

All trials with a study site in Connecticut

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.